211 related articles for article (PubMed ID: 20736370)
1. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.
Xiong S; Pant V; Suh YA; Van Pelt CS; Wang Y; Valentin-Vega YA; Post SM; Lozano G
Cancer Res; 2010 Sep; 70(18):7148-54. PubMed ID: 20736370
[TBL] [Abstract][Full Text] [Related]
2. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F
Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193
[TBL] [Abstract][Full Text] [Related]
3. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.
Xiong S; Pant V; Zhang Y; Aryal NK; You MJ; Kusewitt D; Lozano G
J Pathol; 2017 Mar; 241(4):501-510. PubMed ID: 27925213
[TBL] [Abstract][Full Text] [Related]
4. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
5. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 and Mdm4 loss regulates distinct p53 activities.
Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
[TBL] [Abstract][Full Text] [Related]
7. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
[TBL] [Abstract][Full Text] [Related]
8. Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.
De Clercq S; Gembarska A; Denecker G; Maetens M; Naessens M; Haigh K; Haigh JJ; Marine JC
Mol Cell Biol; 2010 Nov; 30(22):5394-405. PubMed ID: 20855528
[TBL] [Abstract][Full Text] [Related]
9. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
Mancini F; Pieroni L; Monteleone V; LucĂ R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F
Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923
[TBL] [Abstract][Full Text] [Related]
10. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
11. MDM4 is a key therapeutic target in cutaneous melanoma.
Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
[TBL] [Abstract][Full Text] [Related]
12. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities.
Valentin-Vega YA; Box N; Terzian T; Lozano G
Differentiation; 2009 Jun; 77(5):442-9. PubMed ID: 19371999
[TBL] [Abstract][Full Text] [Related]
13. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
14. MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage.
Di Conza G; Mancini F; Buttarelli M; Pontecorvi A; Trimarchi F; Moretti F
Cell Cycle; 2012 Feb; 11(4):749-60. PubMed ID: 22374672
[TBL] [Abstract][Full Text] [Related]
15. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
[TBL] [Abstract][Full Text] [Related]
16. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
17. Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice.
Fong MY; Farghaly H; Kakar SS
BMC Cancer; 2012 Nov; 12():532. PubMed ID: 23164239
[TBL] [Abstract][Full Text] [Related]
18. Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development.
Zhang Q; He X; Chen L; Zhang C; Gao X; Yang Z; Liu G
J Pathol; 2012 Nov; 228(3):416-28. PubMed ID: 22821713
[TBL] [Abstract][Full Text] [Related]
19. Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies.
Cao L; Fan L; Xu W; Li JY
Curr Cancer Drug Targets; 2015; 15(9):769-80. PubMed ID: 26567881
[TBL] [Abstract][Full Text] [Related]
20. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]